Valproic Acid (VPA) is a primary treatment for epilepsy and bipolar disorder. However, prenatal exposure is linked to serious developmental risks, particularly cardiotoxicity. Recent research highlights how metformin cardiotoxicity protection might offer a solution by restoring cellular health through the AMPK/PGC-1α axis.

Mechanisms of Metformin Cardiotoxicity Protection

The study found that VPA suppresses critical pathways responsible for mitochondrial energy and redox balance. Specifically, it reduces the activity of the AMPK/PGC-1α axis. This suppression leads to oxidative stress, evidenced by increased malondialdehyde (MDA) and decreased glutathione (GSH) levels. Consequently, embryos exposed to VPA exhibit bradycardia and reduced cardiac output.

Metformin, a well-known AMPK activator, effectively reverses these damages. Furthermore, it restores the expression of cardiac genes such as amhc and vmhc. By re-establishing mitochondrial homeostasis, metformin preserves cardiac function and structural integrity during early development.

Impact on Mitochondrial and Redox Homeostasis

Restoring redox balance is essential for embryonic heart health. Metformin exposure significantly boosted superoxide dismutase (SOD) activity and normalized nitric oxide levels. In addition, it enhanced the expression of mitochondrial genes. Therefore, researchers believe metformin’s pleiotropic effects provide a robust defense against VPA-induced oxidative insults. This protection is critical, especially since no targeted pharmacological countermeasure currently exists for VPA-induced developmental toxicity.

Frequently Asked Questions

How does Valproic Acid affect heart development?

VPA inhibits the AMPK/PGC-1α axis, which leads to mitochondrial dysfunction and oxidative stress. This results in cardiac edema, bradycardia, and decreased ventricular ejection fraction in developing embryos.

Can Metformin prevent VPA-induced cardiac defects?

In zebrafish models, Metformin successfully prevented structural and functional heart damage. It achieved this by activating the AMPK pathway, which restored energy production and balanced the antioxidant defense system.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.

References

1. Üstündağ ÜV et al. Metformin attenuates valproic acid-induced developmental cardiotoxicity through activation of the AMPK/PGC-1α axis and restoration of mitochondrial and redox homeostasis in zebrafish embryos. Drug Chem Toxicol. 2026 Jun 08. doi: 10.1080/01480545.2026.2684476. PMID: 42260326.


2. Wang J et al. Sodium valproate-induced congenital cardiac abnormalities in mice are associated with the inhibition of histone deacetylase. J Biomed Sci. 2010;17(1):16. doi: 10.1186/1423-0127-17-16.


3. Sasaki H et al. Activation of AMPK by Metformin Improves Left Ventricular Function and Survival in Heart Failure. Cardiovasc Res. 2009;81(2):370-380. doi: 10.1093/cvr/cvn337.